{
    "clinical_study": {
        "@rank": "129426", 
        "acronym": "RIFAMARA", 
        "arm_group": {
            "arm_group_label": "Maraviroc", 
            "arm_group_type": "Experimental", 
            "description": "Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin\nSubstance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose:  oral, 300 mg (1 tablet) twice daily\nSubstance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
        }, 
        "brief_summary": {
            "textblock": "Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to\n      characterize the pharmacokinetic properties of maraviroc alone and when administered with\n      rifabutin and to assess rifabutin and 25-O-desacetyl-rifabutin pharmacokinetics compared to\n      the literature."
        }, 
        "brief_title": "A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV Infection", 
            "HIV-1 Infection", 
            "Mycobacterium Avium Complex (MAC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Mycobacterium Infections", 
                "Mycobacterium avium-intracellulare Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able and willing to sign informed consent prior to any study-related activities.\n\n          -  Male or female participants between 18 and 65 years of age inclusive.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  Healthy, i.e. not suffering from an acute or chronic illness and not using\n             medications.\n\n          -  Acceptable medical history, physical examination, and 12-lead ECG at screening.\n\n          -  Acceptable laboratory values that indicate adequate baseline organ function at\n             screening visit.\n\n          -  Willing to stop using any herbal or natural health products for 2 weeks prior to and\n             during the study including: Grapefruit, grapefruit juice, St. John's Wort.\n\n          -  Willingness to abstain from alcohol use for 3 days prior to and during the study.\n\n          -  Participant must practice a reliable method of birth control while they are\n             participating in the study; for instance an intrauterine device (IUD), condom with\n             spermicidal gel or foam, diaphragm with spermicidal gel or foam, vasectomy, tubal\n             ligation, hysterectomy or abstinence or female must be post menopausal for at least\n             one year.\n\n        Exclusion Criteria:\n\n          -  Have serological evidence of exposure to HIV\n\n          -  Female patients of childbearing potential who has a positive urine pregnancy test at\n             screening\n\n          -  Participants  not willing to use a reliable method of barrier contraception during\n             the study.\n\n          -  Is breastfeeding.\n\n          -  Inability to adhere to protocol.\n\n          -  Use of any medications (2 weeks prior to or during the study) other than occasional\n             use of acetaminophen.\n\n          -  Participants taking oral contraceptive medications.\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  Patients may be excluded from the study for other reasons, at the investigator's\n             discretion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894776", 
            "org_study_id": "2013 0080-01H"
        }, 
        "intervention": [
            {
                "arm_group_label": "Maraviroc", 
                "description": "Substance:\t\tRifabutin Daily dose:\t\toral, 300 mg once daily (8:00 am) for 10 days", 
                "intervention_name": "Rifabutin", 
                "intervention_type": "Drug", 
                "other_name": "Mycobutin, RFB"
            }, 
            {
                "arm_group_label": "Maraviroc", 
                "description": "Substance maraviroc daily dose 300 mg  twice daily (8:00 am and 8:00 pm) for 15 days", 
                "intervention_name": "Maraviroc", 
                "intervention_type": "Drug", 
                "other_name": "Celsentri, MVC"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rifabutin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "healthy volunteers", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ottawa", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "K1H 8L6"
                }, 
                "name": "The Ottawa Hospital -General Campus"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc", 
        "overall_official": {
            "affiliation": "The Ottawa Hospital, Ottawa Hospital Research Institute, University of Ottawa", 
            "last_name": "Donald W Cameron, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Maraviroc pharmacokinetics  AUC, Cmax and C12   with and without rifabutin Rifabutin and 25-O-desacetyl-rifabutin AUC, Cmax and C24", 
            "measure": "pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "15 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894776"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "description and frequency of adverse events for all participants during the study.", 
            "measure": "safety/tolerability of the treatments", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "source": "Ottawa Hospital Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ottawa Hospital Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}